Tech Company Financing Transactions

Sigilon Therapeutics Funding Round

Sigilon Therapeutics closed a $80.3 million Series B funding round on 3/18/2020. Investors included BlackRock, Canada Pension Plan Investment Board and Eli Lilly and Company.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series B
Proceeds Purpose
The funding will support the first-in-human clinical trial of Sigilon's novel encapsulated cell therapy for hemophilia A, expected to begin in the first half of 2020, as well as continued advancement and expansion of Sigilon's programs in rare blood disorders, lysosomal diseases and endocrine and immune disorders.

Company Information

Company Status
Mailing Address
100 Binney St. 600
Cambridge, MA 02142
Email Address
Sigilon Therapeutics (Nasdaq: SGTX) was founded and created by Flagship Pioneering. Sigilon Therapeutics is developing treatments for chronic diseases using new biomaterials, developed at the Massachusetts Institute of Technology (MIT), that can shield implanted cells from immune attack.
Sigilon Therapeutics LinkedIn Company Profile
Social Media
Sigilon Therapeutics Company Twitter Account
Company News
Sigilon Therapeutics News
Sigilon Therapeutics on Facebook
Sigilon Therapeutics on YouTube

Management Team

Email & Social
Chief Executive Officer
Rogerio Vivaldi
  Rogerio Vivaldi LinkedIn Profile  Rogerio Vivaldi Twitter Account  Rogerio Vivaldi News  Rogerio Vivaldi on Facebook
Chief Financial Officer
Glenn Reicin
  Glenn Reicin LinkedIn Profile  Glenn Reicin Twitter Account  Glenn Reicin News  Glenn Reicin on Facebook
Chief Medical Officer
Deya Corzo
  Deya Corzo LinkedIn Profile  Deya Corzo Twitter Account  Deya Corzo News  Deya Corzo on Facebook
Chief Technical Officer
David Peritt
  David Peritt LinkedIn Profile  David Peritt Twitter Account  David Peritt News  David Peritt on Facebook
Vice President
Hozefa Bandukwala
  Hozefa Bandukwala LinkedIn Profile  Hozefa Bandukwala Twitter Account  Hozefa Bandukwala News  Hozefa Bandukwala on Facebook
Vice President
Olivia Kelly
  Olivia Kelly LinkedIn Profile  Olivia Kelly Twitter Account  Olivia Kelly News  Olivia Kelly on Facebook
VP - Bus. Development
Anne Altmeyer
  Anne Altmeyer LinkedIn Profile  Anne Altmeyer Twitter Account  Anne Altmeyer News  Anne Altmeyer on Facebook
VP - Engineering
Susan Drapeau
  Susan Drapeau LinkedIn Profile  Susan Drapeau Twitter Account  Susan Drapeau News  Susan Drapeau on Facebook
VP - Finance
Josias Pontes
  Josias Pontes LinkedIn Profile  Josias Pontes Twitter Account  Josias Pontes News  Josias Pontes on Facebook
VP - General Counsel
Melodie Henderson
  Melodie Henderson LinkedIn Profile  Melodie Henderson Twitter Account  Melodie Henderson News  Melodie Henderson on Facebook
VP - General Counsel
Matthew Kowalsky
  Matthew Kowalsky LinkedIn Profile  Matthew Kowalsky Twitter Account  Matthew Kowalsky News  Matthew Kowalsky on Facebook
VP - Human Resources
Vanya Sagar
  Vanya Sagar LinkedIn Profile  Vanya Sagar Twitter Account  Vanya Sagar News  Vanya Sagar on Facebook
VP - Manufacturing
Martha Rook
  Martha Rook LinkedIn Profile  Martha Rook Twitter Account  Martha Rook News  Martha Rook on Facebook
VP - Operations
Devyn Smith
  Devyn Smith LinkedIn Profile  Devyn Smith Twitter Account  Devyn Smith News  Devyn Smith on Facebook



Browse more venture capital transactions:

Prev: 3/18/2020: Rheaply venture capital transaction
Next: 3/18/2020: RoadRunner Recycling venture capital transaction


Share this article


About Database of VC Transactions

We record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary